Our top pick for
Compugen Ltd is a biotechnology business based in the US. Compugen shares (CGEN) are listed on the NASDAQ and all prices are listed in US Dollars. Compugen employs 68 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$6.14|
|52-week range||$5.76 - $15.16|
|50-day moving average||$6.34|
|200-day moving average||$7.26|
|Wall St. target price||$20.86|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-0.43|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-15)||-3.46%|
|1 month (2021-09-24)||-1.29%|
|3 months (2021-07-23)||-7.95%|
|6 months (2021-04-23)||-29.67%|
|1 year (2020-10-23)||-56.64%|
|2 years (2019-10-24)||45.15%|
|3 years (2018-10-24)||98.71%|
|5 years (2016-10-24)||4.07%|
|Revenue TTM||$2 million|
|Gross profit TTM||$1.9 million|
|Return on assets TTM||-17.34%|
|Return on equity TTM||-30.68%|
|Market capitalisation||$538.9 million|
TTM: trailing 12 months
There are currently 6.4 million Compugen shares held short by investors – that's known as Compugen's "short interest". This figure is 6.8% down from 6.9 million last month.
There are a few different ways that this level of interest in shorting Compugen shares can be evaluated.
Compugen's "short interest ratio" (SIR) is the quantity of Compugen shares currently shorted divided by the average quantity of Compugen shares traded daily (recently around 617921.44927536). Compugen's SIR currently stands at 10.35. In other words for every 100,000 Compugen shares traded daily on the market, roughly 10350 shares are currently held short.
However Compugen's short interest can also be evaluated against the total number of Compugen shares, or, against the total number of tradable Compugen shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Compugen's short interest could be expressed as 0.08% of the outstanding shares (for every 100,000 Compugen shares in existence, roughly 80 shares are currently held short) or 0.0958% of the tradable shares (for every 100,000 tradable Compugen shares, roughly 96 shares are currently held short).
A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Compugen.
Find out more about how you can short Compugen stock.
We're not expecting Compugen to pay a dividend over the next 12 months.
Over the last 12 months, Compugen's shares have ranged in value from as little as $5.76 up to $15.16. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Compugen's is 2.3159. This would suggest that Compugen's shares are significantly more volatile than the average for this exchange and represent a higher risk.
Compugen Ltd. , a clinical-stage therapeutic discovery and development company, engages in the research, development, and commercialization of therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; BAY 1905254, a therapeutic antibody targeting ILDR2, which is in Phase I clinical study in patients with solid tumors; and COM902, a therapeutic antibody targeting TIGIT. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused primarily on myeloid targets. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics for antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd.
Steps to owning and managing ProShares Bitcoin Strategy ETF units.
Everything we know about the The Real Good Food Company IPO, plus information on how to buy in.
Everything we know about the Lulu’s Fashion Lounge Holdings IPO, plus information on how to buy in.
Everything we know about the Allarity Therapeutics IPO, plus information on how to buy in.
Everything we know about the Jupiter Neurosciences IPO, plus information on how to buy in.
Everything we know about the Mainz Biomed IPO, plus information on how to buy in.
Everything we know about the Progressive Care IPO, plus information on how to buy in.
Everything we know about the Desert Peak Minerals IPO, plus information on how to buy in.
Everything we know about the Vaxxinity IPO, plus information on how to buy in.
Everything we know about the Entrada Therapeutics IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.